- NeoStem (NBS -11.1%) started the day in positive territory but quickly faded into the red and is now down double-digits.
- It looks likely that an article by SA contributor Probio Invest is weighing on the shares.
- Probio says a study that showed autologous stem cells did not boost heart function "clearly does not bode well for NBS' AMR-001."
NeoStem falls, author questions AMR-001 after study results
From other sites
at Nasdaq.com (Dec 15, 2014)
at MarketWatch.com (Jul 13, 2011)
at MarketWatch.com (Nov 16, 2010)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs